These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17625780)

  • 41. Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen.
    Huesgen E; Burgos R; Goldstein DA; Max B; Jarrett OD
    Antivir Ther; 2012; 17(7):1385-8. PubMed ID: 22728657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hypertension, HIV infection, and highly active antiretroviral therapy].
    Bernardino de la Serna JI; Zamora FX; Montes ML; García-Puig J; Arribas JR
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):32-7. PubMed ID: 19409669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of darunavir on lipid profile in HIV-infected patients.
    Overton ET; Arathoon E; Baraldi E; Tomaka F
    HIV Clin Trials; 2012; 13(5):256-70. PubMed ID: 23134626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
    Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
    J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.
    Badiou S; De Boever CM; Dupuy AM; Baillat V; Cristol JP; Reynes J
    AIDS; 2003 Mar; 17(5):772-4. PubMed ID: 12646808
    [No Abstract]   [Full Text] [Related]  

  • 47. [Metabolic disturbances associated with HAART].
    Olczak A
    Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).
    Nunes EP; Santini de Oliveira M; Merçon M; Zajdenverg R; Faulhaber JC; Pilotto JH; Ribeiro JE; Norton M; Schechter M
    HIV Clin Trials; 2009; 10(6):368-74. PubMed ID: 20133267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
    Loutfy MR; Ackad N; Antoniou T; Baril JG; Conway B; de Wet J; Trottier B; Kovacs CM; Thompson W; Martel AY; Trottier S; Rouleau D; Shafran SD; Rachlis A; Fraser C; Smaill F; Walmsley SL; Tseng AL; Sampalis JS
    HIV Clin Trials; 2007; 8(5):259-68. PubMed ID: 17956827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Another emerging event occurring during HIV infection treated with any antiretroviral therapy: frequency and role of gynecomastia.
    Manfredi R; Calza L; Chiodo F
    Infez Med; 2004 Mar; 12(1):51-9. PubMed ID: 15329529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
    Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
    Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Focal mycobacterial lymphadenitis after starting highly active antiretroviral therapy].
    Schwietert M; Battegay M
    Dtsch Med Wochenschr; 1999 Jan; 124(3):45-8. PubMed ID: 9987485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Protease inhibitors].
    Tachikawa N
    Kansenshogaku Zasshi; 2005 Dec; 79(12):905-30. PubMed ID: 16444973
    [No Abstract]   [Full Text] [Related]  

  • 57. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
    Hirsch HH; Battegay M
    Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Getting to the HAART of insulin resistance.
    Nolan D; Mallal S
    AIDS; 2001 Oct; 15(15):2037-41. PubMed ID: 11600834
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.